TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8643226

Group type: EXPERIMENTAL
Intervention: Dietician counseling aimed at weight maintenance
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (no formalized dietician counseling)
Number of subjects: 107
Study: 1614462

Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin (500 mg per kilogram of body weight per day)
Number of subjects: 588

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin
Number of subjects: 588
Study: 6998552

Group type: EXPERIMENTAL
Intervention: Clonidine, 0.05 mg twice daily
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 30954330

Group type: EXPERIMENTAL
Intervention: Neuropattern oriented exploratory treatment (intervention group, IG)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Standard care (treatment as usual, standard group, SG)
Number of subjects: 178
Study: 28416827

Group type: EXPERIMENTAL
Intervention: Direct Anterior Approach (DAA)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Posterolateral Piriformis-sparing Approach (Mis-PLA)
Number of subjects: 82
Study: 26011509

Group type: EXPERIMENTAL
Intervention: CABG and optimal medical therapy (MED)
Number of subjects: 1212

Group type: COMPARATOR
Intervention: MED alone
Number of subjects: 1212
Study: 23803797

Group type: EXPERIMENTAL
Intervention: Psychic Representation focused Psychotherapy (PRFP) - 20 sessions
Number of subjects: 53

Group type: COMPARATOR
Intervention: Treatment as usual (Control group) - 26 patients
Number of subjects: 53
Study: 21860046

Group type: EXPERIMENTAL
Intervention: Social cognition
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Social cognition and other variables (motivation, social competence)
Number of subjects: 148
Study: 19347726

Group type: EXPERIMENTAL
Intervention: XM02 (5 microg/kg/day, subcutaneous, for at least 5 days and a maximum of 14 days)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Filgrastim (5 microg/kg/day, subcutaneous, for at least 5 days and a maximum of 14 days)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: XM02
Number of subjects: 92

Group type: COMPARATOR
Intervention: Filgrastim
Number of subjects: 92
Study: 17721960

Group type: EXPERIMENTAL
Intervention: Dissociation induction via audiophotic stimulation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Credible control condition
Number of subjects: 120
Study: 17036619

Group type: EXPERIMENTAL
Intervention: Exercise alone
Number of subjects: 1092

Group type: EXPERIMENTAL
Intervention: Exercise and cognitive-behavioral therapy
Number of subjects: 1092
Study: 12707157

Group type: EXPERIMENTAL
Intervention: Clonidine 15 micro g with bupivacaine 6 mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Clonidine 30 micro g with bupivacaine 6 mg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Bupivacaine 6 mg with saline (Control Group B)
Number of subjects: 45
Study: 10626094

Group type: EXPERIMENTAL
Intervention: Lazabemide
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 8574749

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 5 mg/kg intravenous infusion over 180 min
Number of subjects: 23

Group type: COMPARATOR
Intervention: Physiological saline (Control)
Number of subjects: 23
Study: 2077492

Group type: EXPERIMENTAL
Intervention: Autopolymerized Delton fissure sealants
Number of subjects: 73

Group type: COMPARATOR
Intervention: Light-polymerized Delton fissure sealants
Number of subjects: 73
Study: 6452297

Group type: EXPERIMENTAL
Intervention: Topical erythromycin (1%) in a new penetrative vehicle
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 31628271

Group type: EXPERIMENTAL
Intervention: Early controlled aerobic exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care or delayed exercise
Number of subjects: 0
Study: 29730375

Group type: EXPERIMENTAL
Intervention: Ranger paclitaxel-coated balloon (DCB)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Uncoated balloon angioplasty (control)
Number of subjects: 105
Study: 26768873

Group type: EXPERIMENTAL
Intervention: Endoscope-assisted keyhole technique
Number of subjects: 184

Group type: COMPARATOR
Intervention: Traditional craniotomy
Number of subjects: 184
Study: 25669083

Group type: EXPERIMENTAL
Intervention: Intercostal analgesia (ICA) with 2 ml x hr(‐1) of 0.2% ropivacaine and intravenous fentanyl (0.25 x μg(‐1). kg(‐1) x hr(‐1))
Number of subjects: 22

Group type: COMPARATOR
Intervention: Epidural analgesia with 2 ml x hr(‐1) of 0.2% ropivacaine and intravenous fentanyl (0.25 x μg(‐1). kg(‐1) x hr(‐1))
Number of subjects: 22
Study: 23368423

Group type: EXPERIMENTAL
Intervention: Nurse case management (NCM) with motivational interviewing (MI)
Number of subjects: 545

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 545
Study: 20417488

Group type: EXPERIMENTAL
Intervention: IL1beta‐511 minor allele
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: IL6‐176 minor allele
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: IL4R‐148 minor allele
Number of subjects: 272
Study: 19001265

Group type: EXPERIMENTAL
Intervention: Intralymphatic allergen administration (3 injections over 2 months, cumulative allergen dose 3,000 SQ-U)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Intralymphatic allergen administration
Number of subjects: 165

Group type: COMPARATOR
Intervention: s.c. immunotherapy (54 injections over 3 years, cumulative allergen dose 4,031,540 SQ-U)
Number of subjects: 165
Study: 16280777

Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CyA) 1.5 mg/kg twice daily
Number of subjects: 64

Group type: COMPARATOR
Intervention: Pentosan polysulfate sodium (PPS) 100 mg 3 times daily
Number of subjects: 64
Study: 12182757

Group type: EXPERIMENTAL
Intervention: 200 mg of intravenous erythromycin
Number of subjects: 20

Group type: COMPARATOR
Intervention: 4 mg of intravenous ondansetron (10 subjects)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 50 micro g octreotide
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10645353

Group type: EXPERIMENTAL
Intervention: Intra-articular lignocaine (IAL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Entonox
Number of subjects: 0
Study: 8523317

Group type: EXPERIMENTAL
Intervention: Nylon vertical mattress sutures
Number of subjects: 93

Group type: COMPARATOR
Intervention: Interrupted subcuticular polydioxanone (PDS) sutures
Number of subjects: 93
Study: 2027658

Group type: EXPERIMENTAL
Intervention: Computer Orthoptics Diagnostic Program
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard Lens Flipper Method
Number of subjects: 40
Study: 7327728

Group type: EXPERIMENTAL
Intervention: Dimon and Hughston osteotomy
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Sarmiento osteotomy
Number of subjects: 150

Group type: COMPARATOR
Intervention: Skeletal traction with a tibial pin
Number of subjects: 150
Study: 31414269

Group type: EXPERIMENTAL
Intervention: Sildenafil (0.5 mg/kg every 6 hours)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 40
Study: 27312566

Group type: EXPERIMENTAL
Intervention: Watching TV for > 1 hour/day during weekdays
Number of subjects: 6431
Study: 25835642

Group type: EXPERIMENTAL
Intervention: Oral misoprostol (600μg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Intramuscular oxytocin (1mL of 10IU)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Oral misoprostol
Number of subjects: 200
Study: 24237999

Group type: EXPERIMENTAL
Intervention: Etanercept monotherapy
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: Etanercept with methotrexate
Number of subjects: 682
Study: 21349938

Group type: EXPERIMENTAL
Intervention: Riboflavin 0.1% and ultraviolet A (370 nm at 3 mW/cm(2))
Number of subjects: 24
Study: 19805689

Group type: EXPERIMENTAL
Intervention: Augmented therapy (intensive postinduction treatment)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 262
Study: 17220608

Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m2 x 4 weekly infusions)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Rituximab (phase I study)
Number of subjects: 90
Study: 15610331

Group type: EXPERIMENTAL
Intervention: 5% weight loss
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: 10% weight loss
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: 20% weight loss
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Current weight
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: 10% weight loss among obese patients
Number of subjects: 365
Study: 11061678

Group type: EXPERIMENTAL
Intervention: WeiniCom
Number of subjects: 42

Group type: COMPARATOR
Intervention: buprenorphine
Number of subjects: 42
Study: 9306142

Group type: EXPERIMENTAL
Intervention: Normal subjects
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Patients with left ventricular aneurysm
Number of subjects: 19

Group type: COMPARATOR
Intervention: Comparison between normal subjects and patients with LV aneurysm
Number of subjects: 19
Study: 8326971

Group type: EXPERIMENTAL
Intervention: Anistreplase administered before admission (prehospital group)
Number of subjects: 5469

Group type: COMPARATOR
Intervention: Anistreplase administered in the hospital (hospital group)
Number of subjects: 5469

Group type: EXPERIMENTAL
Intervention: Prehospital group
Number of subjects: 5469

Group type: COMPARATOR
Intervention: Hospital group
Number of subjects: 5469
Study: 3097691

Group type: EXPERIMENTAL
Intervention: Lithium with partial sleep deprivation (PSD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo with partial sleep deprivation (PSD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lithium alone without PSD
Number of subjects: 0
Study: 30572161

Group type: EXPERIMENTAL
Intervention: New salad bars
Number of subjects: 6804

Group type: EXPERIMENTAL
Intervention: Salad bars with marketing intervention
Number of subjects: 6804

Group type: EXPERIMENTAL
Intervention: Salad bars
Number of subjects: 6804

Group type: COMPARATOR
Intervention: Traditional serving methods
Number of subjects: 6804
Study: 30026128

Group type: EXPERIMENTAL
Intervention: WL + SitLess
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: WL + EX
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: WL + EX + SitLess
Number of subjects: 180
Study: 27522312

Group type: EXPERIMENTAL
Intervention: 2% lidocaine 2 ml with dexmedetomidine 14 μg peripherally
Number of subjects: 90

Group type: COMPARATOR
Intervention: 2% lidocaine 2 ml only (control)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 2% lidocaine 2 ml with dexmedetomidine 14 μg systemically
Number of subjects: 90
Study: 24477514

Group type: EXPERIMENTAL
Intervention: MBSR(BC) intervention group
Number of subjects: 41

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 41
Study: 22710563

Group type: EXPERIMENTAL
Intervention: Peer-led, community-based chronic disease self-management program
Number of subjects: 582

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 582
Study: 20695899

Group type: EXPERIMENTAL
Intervention: Elemental diet treatment
Number of subjects: 0
Study: 18192787

Group type: EXPERIMENTAL
Intervention: Polymerase chain reaction-based diagnostics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment of T. vaginalis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Control interventions for T. vaginalis
Number of subjects: 0
Study: 15802410

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system
Number of subjects: 62

Group type: COMPARATOR
Intervention: Copper T 380A intrauterine device
Number of subjects: 62
Study: 12795730

Group type: EXPERIMENTAL
Intervention: Limited intervention (provider educational session and examination room posters)
Number of subjects: 1518

Group type: EXPERIMENTAL
Intervention: Full intervention (provider educational session, examination room posters, and completion of ICE module)
Number of subjects: 1518

Group type: EXPERIMENTAL
Intervention: Limited intervention
Number of subjects: 1518

Group type: EXPERIMENTAL
Intervention: Full intervention
Number of subjects: 1518
Study: 16676932

Group type: EXPERIMENTAL
Intervention: Syrinx decompression combined with spinal cord untethering
Number of subjects: 30

Group type: COMPARATOR
Intervention: Spinal cord untethering alone
Number of subjects: 30
Study: 8923069

Group type: EXPERIMENTAL
Intervention: Weaning protocol
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 101
Study: 1409461

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg + hydrochlorothiazide (HCTZ) 25 mg
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 4010387

Group type: EXPERIMENTAL
Intervention: 3 X 75 mg pirlindol daily for two weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 300 mg pirlindol (single dose)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 3 X 75 mg pirlindol (after one week treatment)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 75 mg and 225 mg pirlindol (superimposed dosage on days 8 and 15)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Evaluation of blood pressure, pulse rate and side effects
Number of subjects: 10
Study: 31424244

Group type: EXPERIMENTAL
Intervention: 4-month YMCA gym membership plus a 16-week integrated motivational intervention for exercise (MI + CM)
Number of subjects: 66

Group type: COMPARATOR
Intervention: 4-month YMCA gym membership only (MO)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both study conditions (MO and MI + CM)
Number of subjects: 66
Study: 31298269

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-density lipoprotein cholesterol (HDL-C)
Number of subjects: 0
Study: 27769697

Group type: EXPERIMENTAL
Intervention: Water Resistance Therapy (WRT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tube Phonation with the distal end in air (TPA)
Number of subjects: 20
Study: 26052866

Group type: EXPERIMENTAL
Intervention: Darexaban 15 mg bid
Number of subjects: 1297

Group type: EXPERIMENTAL
Intervention: Darexaban 30 mg qd
Number of subjects: 1297

Group type: EXPERIMENTAL
Intervention: Darexaban 30 mg bid
Number of subjects: 1297

Group type: EXPERIMENTAL
Intervention: Darexaban 60 mg qd
Number of subjects: 1297

Group type: EXPERIMENTAL
Intervention: Darexaban 60 mg bid
Number of subjects: 1297

Group type: EXPERIMENTAL
Intervention: Darexaban 120 mg qd
Number of subjects: 1297

Group type: COMPARATOR
Intervention: Warfarin qd
Number of subjects: 1297

Group type: EXPERIMENTAL
Intervention: Darexaban (all doses)
Number of subjects: 1297

Group type: EXPERIMENTAL
Intervention: Darexaban
Number of subjects: 1297
Study: 23584270

Group type: EXPERIMENTAL
Intervention: Three-dimensional overlay
Number of subjects: 72

Group type: COMPARATOR
Intervention: Gel group (control)
Number of subjects: 72
Study: 22118256

Group type: EXPERIMENTAL
Intervention: Body-weight-supported treadmill training (BWSTT)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Tilt-table standing (TTS)
Number of subjects: 7
Study: 19114261

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation combined with cognitive behavioral therapy for insomnia (CBT-I)
Number of subjects: 21
Study: 17145604

Group type: EXPERIMENTAL
Intervention: Anticoagulation (specifics not provided)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multicenter randomized controlled trials (not yet conducted)
Number of subjects: 0
Study: 15317636

Group type: EXPERIMENTAL
Intervention: Brief behavioural intervention (BBI) based on the Blood‐Borne Virus Transmission Risk Assessment Questionnaire (BBV‐TRAQ), tailored 30-minute session
Number of subjects: 145

Group type: COMPARATOR
Intervention: Standardized educational intervention
Number of subjects: 145
Study: 11342997

Group type: EXPERIMENTAL
Intervention: Naftidrofuryl 200 mg tid for six months
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study: 7943509

Group type: EXPERIMENTAL
Intervention: semirigid ankle stabilizer
Number of subjects: 1601
Study: 3069477

Group type: EXPERIMENTAL
Intervention: Pentazocine (PZ) 30 mg i.m.
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Amitriptyline (AMI) 50 mg p.o.
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Subchronic AMI + acute PZ
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Subchronic AMI
Number of subjects: 11
Study: 1703428

Group type: EXPERIMENTAL
Intervention: Buflomedil
Number of subjects: 81

Group type: COMPARATOR
Intervention: Guanethidine
Number of subjects: 81
Study: 4899996

Group type: EXPERIMENTAL
Intervention: Phenacetin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study: 31627998

Group type: EXPERIMENTAL
Intervention: Bisoprolol 8mg transdermal patch at bedtime
Number of subjects: 63

Group type: COMPARATOR
Intervention: Standard protocol
Number of subjects: 63
Study: 30782208

Group type: EXPERIMENTAL
Intervention: Gyejigachulbutang (2.5 g three times a day for 4 weeks)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (2.5 g three times a day for 4 weeks)
Number of subjects: 80
Study: 28808144

Group type: EXPERIMENTAL
Intervention: Real air purifiers
Number of subjects: 55

Group type: COMPARATOR
Intervention: Sham air purifiers
Number of subjects: 55
Study: 27326445

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prasugrel (titrated dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prasugrel (pretreatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prasugrel (timing of administration)
Number of subjects: 0
Study: 24061784

Group type: EXPERIMENTAL
Intervention: Citalopram (10 mg/5 mL) for 12 weeks, with a mean maximum dose of 16.5 mg daily (maximum 20 mg/d)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 149
Study: 21571150

Group type: EXPERIMENTAL
Intervention: Hydroxycarbamide (20 mg/kg per day for 2 years)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study: 19713405

Group type: EXPERIMENTAL
Intervention: Yakson
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Gentle Human Touch (GHT)
Number of subjects: 40
Study: 16765007

Group type: EXPERIMENTAL
Intervention: Adefovir (PMEA) measured using LC-MS/MS method in human serum
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adefovir (PMEA) measured using LC-MS/MS method in human urine
Number of subjects: 0
Study: 12757688

Group type: EXPERIMENTAL
Intervention: Chloroquine and proguanil
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Mefloquine
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Atovaquone and proguanil
Number of subjects: 320

Group type: COMPARATOR
Intervention: Control group (no prophylaxis or other drugs)
Number of subjects: 320
Study: 11516001

Group type: EXPERIMENTAL
Intervention: Immediate loading of implants with overdentures
Number of subjects: 10

Group type: COMPARATOR
Intervention: Delayed loading of implants with overdentures
Number of subjects: 10
Study: 9767835

Group type: EXPERIMENTAL
Intervention: Classical technique for saphenous vein dissection (Group I)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Video-surgery technique for saphenous vein dissection (Group II)
Number of subjects: 60
Study: 8144761

Group type: EXPERIMENTAL
Intervention: Immediate coronary angioplasty
Number of subjects: 301

Group type: COMPARATOR
Intervention: Intravenous streptokinase
Number of subjects: 301
Study: 3345278

Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg kg‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atracurium (effective doses)
Number of subjects: 0
Study: 31702419

Group type: EXPERIMENTAL
Intervention: M-EI (Methotrexate-Etoposide-Ifosfamide)
Number of subjects: 95

Group type: COMPARATOR
Intervention: API-AI (Doxorubicin-Cisplatin-Ifosfamide)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: M-EI and API-AI
Number of subjects: 95
Study: 28901219

Group type: EXPERIMENTAL
Intervention: Health Wellness Coaching
Number of subjects: 320

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 320
Study: 26585393

Group type: EXPERIMENTAL
Intervention: Problem-Solving Therapy (PST) as add-on to standard outpatient rehabilitation
Number of subjects: 166

Group type: COMPARATOR
Intervention: Standard outpatient rehabilitation only
Number of subjects: 166
Study: 25403813

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Psycho-educative coaching group (OCD-EP)
Number of subjects: 128
Study: 24347774

Group type: EXPERIMENTAL
Intervention: Whitfield's ointment + oral fluconazole (150 mg once a week for 4 weeks)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Topical 1% butenafine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 120
Study: 20492850

Group type: EXPERIMENTAL
Intervention: Aspirin 1000 mg/d
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 18446591

Group type: EXPERIMENTAL
Intervention: School-based administration of preventive asthma medications with dose adjustments according to NHLBI guidelines and a home-based ETS reduction program utilizing motivational interviewing principles.
Number of subjects: 0
Study: 16770112

Group type: EXPERIMENTAL
Intervention: Letrozole (Femara tablet 2.5 mg) given orally once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Letrozole (Femara tablet 2.5 mg)
Number of subjects: 0
Study: 12727970

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy with Premarin or a mixture of estrone and equilin sulfates for 3 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estrogen in the proliferative phase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estrogen in the secretory phase
Number of subjects: 0
Study: 11429666

Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9134634

Group type: EXPERIMENTAL
Intervention: New rapid plasma D-Dimer ELISA measurement
Number of subjects: 448

Group type: COMPARATOR
Intervention: Standard plasma D-Dimer ELISA measurement
Number of subjects: 448